Publication:
Ibero-American Expert Consensus on Squamous Cell Carcinoma of the Head and Neck Treatment in Patients Unable to Receive Cisplatin: Recommendations for Clinical Practice

Simple item page
dc.contributor.authorFalco, Agustín
dc.contributor.authorDe Oliveira, Thiago Bueno
dc.contributor.authorCacicedo Jon
dc.contributor.authorOspina, Aylen Vanessa
dc.contributor.authorTicona, Miguel Ángel
dc.contributor.authorGalindo, Héctor
dc.contributor.authorPereira, Marcos David
dc.contributor.authorAguilar-Ponce, José Luis
dc.contributor.authorRueda-Domínguez, Antonio
dc.contributor.authorSoria, Tannia
dc.contributor.authorTaberna, Miren
dc.contributor.authorIglesias, Lara
dc.contributor.authorSowley, Taysser
dc.contributor.authorMesía, Ricard
dc.contributor.authorTTCC group (Spanish Group for the Treatment of the Head and Neck Cancer)
dc.date.accessioned2023-06-27T12:45:37Z
dc.date.available2023-06-27T12:45:37Z
dc.date.issued2021
dc.description.abstractAbstract: Cisplatin is the standard of treatment for squamous cell carcinoma of the head and neck (SCCHN) that has demonstrated efficacy, either in locally advanced disease when combined with radiotherapy at high doses, or in metastatic/recurrent disease when combined with other agents. However, the usual toxicities related to cisplatin, such as neurotoxicity, nephrotoxicity, ototoxicity, and hematologic toxicities, especially when high doses have been administered, have important implications in the patients’ quality of life. The decision to administer cisplatin depends on several patient factors, such as age, performance status, weight loss, comorbidities, previous toxicities, chronic viral infection, or even the current SARS-CoV-2 pandemic. In order to establish recommendations for the management of patients with SCCHN, a group of experts in medical and radiation oncology from Spain and Latin-American discussed how to identify patients who are not candidates for cisplatin to offer them the most suitable therapeutic alternative. Keywords: age, cisplatin, comorbidities, contraindication, frailty, toxicity
dc.identifier.citationFalco A, de Oliveira TB, Cacicedo J, Ospina AV, Ticona MÁ, Galindo H, Pereira MD, Aguilar-Ponce JL, Rueda-Domínguez A, Soria T, Taberna M, Iglesias L, Sowley T, Mesía R; TTCC group (Spanish Group for the Treatment of the Head and Neck Cancer). Ibero-American Expert Consensus on Squamous Cell Carcinoma of the Head and Neck Treatment in Patients Unable to Receive Cisplatin: Recommendations for Clinical Practice. Cancer Manag Res. 2021 Aug 26;13:6689-6703. doi: 10.2147/CMAR.S322411. PMID: 34471383; PMCID: PMC8405157.
dc.identifier.urihttp://biblioteca.solcaquito.org.ec:9997/handle/123456789/405
dc.language.isoen
dc.publisherCancer Management and Research
dc.titleIbero-American Expert Consensus on Squamous Cell Carcinoma of the Head and Neck Treatment in Patients Unable to Receive Cisplatin: Recommendations for Clinical Practice
dc.typeArticle
dspace.entity.typePublication
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
cmar-13-6689.pdf
Size:
592.11 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
PubMed